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Summary
Background Intrahepatic cholestasis of pregnancy is associated with adverse perinatal outcomes, but the association 
with the concentration of specific biochemical markers is unclear. We aimed to quantify the adverse perinatal effects 
of intrahepatic cholestasis of pregnancy in women with increased serum bile acid concentrations and determine 
whether elevated bile acid concentrations were associated with the risk of stillbirth and preterm birth.
Methods We did a systematic review by searching PubMed, Web of Science, and Embase databases for studies 
published from database inception to June 1, 2018, reporting perinatal outcomes for women with intrahepatic 
cholestasis of pregnancy when serum bile acid concentrations were available. Inclusion criteria were studies defining 
intrahepatic cholestasis of pregnancy based upon pruritus and elevated serum bile acid concentrations, with or 
without raised liver aminotransferase concentrations. Eligible studies were case-control, cohort, and population-
based studies, and randomised controlled trials, with at least 30 participants, and that reported bile acid concentrations 
and perinatal outcomes. Studies at potential higher risk of reporter bias were excluded, including case reports, studies 
not comprising cohorts, or successive cases seen in a unit; we also excluded studies with high risk of bias from 
groups selected (eg, a subgroup of babies with poor outcomes were explicitly excluded), conference abstracts, and 
Letters to the Editor without clear peer review. We also included unpublished data from two UK hospitals. We did a 
random effects meta-analysis to determine risk of adverse perinatal outcomes. Aggregate data for maternal and 
perinatal outcomes were extracted from case-control studies, and individual patient data (IPD) were requested from 
study authors for all types of study (as no control group was required for the IPD analysis) to assess associations 
between biochemical markers and adverse outcomes using logistic and stepwise logistic regression. This study is 
registered with PROSPERO, number CRD42017069134.
Findings We assessed 109 full-text articles, of which 23 studies were eligible for the aggregate data meta-analysis 
(5557 intrahepatic cholestasis of pregnancy cases and 165 136 controls), and 27 provided IPD (5269 intrahepatic 
cholestasis of pregnancy cases). Stillbirth occurred in 45 (0·91%) of 4936 intrahepatic cholestasis of pregnancy cases 
and 519 (0·32%) of 163 947 control pregnancies (odds ratio [OR] 1·46 [95% CI 0·73–2·89]; I²=59·8%). In singleton 
pregnancies, stillbirth was associated with maximum total bile acid concentration (area under the receiver operating 
characteristic curve [ROC AUC]) 0·83 [95% CI 0·74–0·92]), but not alanine aminotransferase (ROC AUC 0·46 
[0·35–0·57]). For singleton pregnancies, the prevalence of stillbirth was three (0·13%; 95% CI 0·02–0·38) of 
2310 intrahepatic cholestasis of pregnancy cases in women with serum total bile acids of less than 40 µmol/L versus 
four (0·28%; 0·08–0·72) of 1412 cases with total bile acids of 40–99 µmol/L (hazard ratio [HR] 2·35 [95% CI 
0·52–10·50]; p=0·26), and versus 18 (3·44%; 2·05–5·37) of 524 cases for bile acids of 100 µmol/L or more (HR 30·50 
[8·83–105·30]; p<0·0001).
Interpretation The risk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton 
pregnancies when serum bile acids concentrations are of 100 µmol/L or more. Because most women with intrahepatic 
cholestasis of pregnancy have bile acids below this concentration, they can probably be reassured that the risk of 
stillbirth is similar to that of pregnant women in the general population, provided repeat bile acid testing is done until 
delivery.
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Introduction
Intrahepatic cholestasis of pregnancy affects 0·1–2% of 
pregnant women;1–4 it is diagnosed in women with 
gestational pruritus and increased serum bile acids, and 
can be complicated by preterm labour, fetal asphyxia, 
meconium-stained amniotic fluid, and stillbirth.5 Results 
from a large Swedish cohort showed that pregnancies in 
which the maternal serum bile acid concentration was of 
40 µmol/L or more were more likely to be complicated 
by spontaneous preterm labour, meconium-stained 
amniotic fluid, and fetal asphyxia.6 A subsequent UK 
cohort study of pregnancy outcome in women with 
intrahepatic cholestasis of pregnancy with serum bile 
acids of 40 µmol/L or more supported these findings and 
also showed an association with intrauterine fetal death 
(adjusted odds ratio 3·05 [95% CI 1·65–5·63] when 
compared with data from 2205 women with uncom-
plicated singleton pregnancies in the UK.7 The asso-
ciation of high maternal serum bile acid concen trations 
with stillbirth is consistent with retrospective studies of 
women with intrahepatic cholestasis of pregnancy in the 
USA8 and Scandinavia.9 The 2007 stillbirth workshop10 
included intrahepatic chole stasis of pregnancy as a 
medical disorder that can cause stillbirth in pregnancies 
when the maternal serum bile acid concentration is 
increased.4,6,7,11
To our knowledge, no studies have been adequately 
powered to assess whether intrahepatic cholestasis of 
pregnancy -associated fetal death occurs above a certain 
bile acid threshold, and clinical guidelines are largely 
reliant upon expert consensus to determine the optimal 
management of affected women.12,13 Clinicians often 
recommend management ranging from surveillance to 
iatrogenic delivery to prevent the subsequent risk of 
fetal death, at gestations typically between 36 weeks and 
40 completed weeks, although the evidence behind this 
approach is scarce.14 Certainly, early delivery is associated 
with short-term neonatal problems and long-term 
issues with impairments in educational performance 
shown with even early-term birth.15,16
We did a systematic review and meta-analysis to 
quantify the adverse perinatal effects of intrahepatic 
cholestasis of pregnancy in women with increased serum 
bile acid concentrations. We also aimed to determine 
whether elevated bile acid concentrations were associated 
with the risk of stillbirth. For the first aim, we extracted 
data from published studies reporting outcomes for 
women with intrahepatic cholestasis of pregnancy and 
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Research in context
Evidence before this study
Intrahepatic cholestasis of pregnancy has been associated 
with increased risks of preterm birth and possibly stillbirth in 
cohort and population studies, yet no consensus has been 
reached within the medical community regarding the 
magnitude of its detrimental effects. Particularly, the adverse 
long-term effects of preterm birth are of relevance to many 
health-care professionals besides those delivering maternity 
care. Evidence from clinical trials and observational studies 
have suggested that disease severity, determined by maternal 
serum bile acid concentrations higher than the typical range, 
is associated with increased risk of adverse perinatal 
outcomes, including stillbirth, preterm birth, meconium 
staining of the amniotic fluid, fetal distress or asphyxia, and 
neonatal unit admission. We searched PubMed, Embase, and 
Web of Science (without language restrictions) for systematic 
reviews and meta-analyses published using the search terms 
“cholestasis”, “pregnancy”, “systematic review”, and 
“meta-analysis”. We found that the effect of drug treatments 
on intrahepatic cholestasis of pregnancy and perinatal 
outcomes stratified by disease severity has been previously 
assessed by meta-analysis, but no study has combined 
existing published literature to assess the effect of increased 
bile acid concentrations in women with intrahepatic 
cholestasis of pregnancy compared with uncomplicated 
pregnancy. We collected individual patient data from 
27 studies, including two unpublished cohorts, with the aim of 
accurately determining how perinatal outcomes are associated 
with bile acid concentrations.
Added value of this study
This study is the first to do individual patient data analysis of 
perinatal outcomes and bile acid concentrations for women 
with intrahepatic cholestasis of pregnancy to show a clear 
association between women with the most severe disease (bile 
acids ≥100 µmol/L) and increased stillbirth risk (in singleton 
pregnancies) compared with those with milder disease and the 
background population.
Implications of all the available evidence
Our study shows that clinical management of women with 
intrahepatic cholestasis of pregnancy with singleton 
pregnancies can be stratified according to the maximum serum 
bile acid concentration, with the majority of women having bile 
acids lower than 100 µmol/L and, therefore, unlikely to have a 
higher risk of stillbirth than the background population. 
The women in our combined cohort were variably managed 
according to study centre, and the high proportion of 
iatrogenic preterm birth for women irrespective of peak bile 
acid concentration might have contributed to the lower 
prevalence of stillbirth observed for women with bile acids of 
less than 100 µmol/L than in some previous studies. Women 
with intrahepatic cholestasis of pregnancy should be managed 
according to their peak bile acid concentration, irrespective of 
treatment with ursodeoxycholic acid, provided repeated bile 
acid testing is done in women at low risk of stillbirth (ie, with 
bile acids <100 µmol/L). Our findings support the use of serum 
bile acid monitoring in cholestasis of pregnancy and provide 
strong support for ensuring that this test is widely available.
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control pregnancies; for the second aim, we did an 
individual patient data (IPD) meta-analysis to determine 
the relationships between biochemical markers and 
adverse perinatal outcomes.
Methods
Search strategy and selection criteria
In this systematic review and meta-analysis we searched 
PubMed, Web of Science, and Embase databases using 
terms relating to intrahepatic cholestasis of pregnancy 
and perinatal outcomes, for articles published from 
database inception to June 1, 2018 (appendix). One add-
itional study was identified by searching reference lists of 
selected studies and two unpublished cohorts from our 
research units were also included. Studies were selected 
for inclusion in one or both groups of the meta-analysis 
based on disease definition, including assessment of 
serum bile acid concentrations and reporting of perinatal 
outcomes. For the aggregate meta-analysis, studies inc-
luding women with intrahepatic cholestasis of pregnancy 
and a control group were included, whereas for the 
IPD analysis, no control group was required. Other wise, 
inclusion criteria were studies reporting bile acid 
concentrations and perinatal outcomes, which defined 
intrahepatic cholestasis of pregnancy based upon pruritus 
with raised serum bile acids with or without elevated 
aminotransferases. Case-control, cohort, and population-
based studies, and randomised controlled trials were 
included. All studies were required to have ethical 
approval to share the data. Excluded studies included 
those at potential risk of increased bias, such as those with 
fewer than 30 participants, case reports, studies not 
comprising cohorts, or successive cases seen in a unit, 
and studies with high risk of bias from groups selected 
(eg, subgroup of babies with poor outcomes was explicitly 
excluded). Conference abstracts and Letters to the Editor 
without peer review were also excluded. We did not have 
language restrictions. When studies were not reported in 
English, electronic translation (Google Translate) was 
used to determine eligibility for inclusion in the meta-
analysis, translating methods and results, with quality of 
translation determined by com pre hensibility (CO); 
following abstract screening, only five manuscripts were 
translated. Study search and selection were done by two 
independent investigators (CO and AS), and a third (CW) 
arbitrated when any conflict occurred in the suitability of a 
study for inclusion. When studies recruited participants 
from the same hospital or population over the same time 
period, the study with the largest number of patients or 
reporting the most relevant outcome data was selected to 
avoid duplication.
Summary estimates were sought from studies with 
control data, to be analysed in an aggregate data meta-
analysis. IPD were requested from corresponding and first 
or last authors by email and online platforms (Researchgate) 
in the language in which the manuscript was written. 
Authors who did not respond on two occasions were 
deemed to have not replied, and for all but one manuscript 
(contact details for other authors could not be found), at 
least two authors were contacted.
Respondents completed standardised spreadsheets, 
and data were standardised (units, equivalent decimal 
places, correct data entry, and categorisation of data 
allocation confirmed) and checked before statistical 
analysis (AS, CDI, and CO). Any disparities in the data 
received were discussed with the original authors.
Approval was obtained from the ethics committee of 
Hammersmith Hospitals National Health Service Trust 
(97/5197 and 08/H0707/21), London, UK, for inclusion of 
pseudoanonymised IPD. Approval was not required for 
the aggregate (extracted) data meta-analysis, because 
these data are anonymised and in the public domain; 
appropriate ethics approval was an inclusion criterion for 
all studies contained within the study.
Unpublished data
Unpublished data from two UK hospitals (Imperial 
College Healthcare National Health Service [NHS] Trust 
and Guy’s and St Thomas’ NHS Foundation Trust, 
London, UK) were included in the IPD analysis. Women 
with intrahepatic cholestasis of pregnancy were identified 
through the antenatal clinics, maternity assessment unit, 
and antenatal wards, and recruited for an observational 
study, during which they prospectively completed health 
questionnaires and provided longitudinal blood samples. 
The study complied with the 1975 Declaration of Helsinki 
guidelines; participants provided written informed 
consent before inclusion. For women with more than 
one pregnancy during the recruitment period, only the 
first recorded pregnancy was included.
Data analysis
Data from studies eligible for case-control aggregate data 
meta-analysis were extracted by two authors indep-
endently (CO and CDI), and any differences in reported 
values confirmed jointly. Maternal and perinatal outcomes 
were extracted, including maximum serum bile acid 
concentrations and liver function tests (maternal factors: 
parity, body-mass index (BMI), age, ethnicity, diabetes, 
hypertension, total bile acid concentration (peak), alanine 
aminotransferase concentration (peak), aspartate amino-
transferase concentration (peak), bili rubin concentration 
(peak), ursodeoxycholic acid treatment, multifetal preg-
nancies, and caesarean section; perinatal outcomes: still-
birth, gestational age at delivery, preterm birth, iatrogenic 
preterm birth, spontaneous preterm birth, Apgar score <7 
at 5 min, asphyxial events, meconium staining of the 
amniotic fluid, neonatal unit admission, and birthweight 
centile). When necessary, mean and SDs were estimated 
from medians using Wan’s method.17 Data were compiled 
into a single dataset and any anomalies checked with the 
study authors.
Quality of the studies included in the aggregate 
data meta-analysis was determined using the 
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Newcastle-Ottawa scale18 independently by two authors 
(CO and CDI). Any disparities in scoring were reviewed 
and consensus obtained following discussion. The 
quality of IPD studies was determined using the National 
Heart, Lung, and Blood Institute quality assessment tool 
for case series studies.19
We calculated mean differences and odds ratios (ORs) 
with GraphPad Prism (version 7.03).
We did a random effects meta-analysis with the 
DerSimonian and Laird method, presenting results as 
odds ratios or weighted mean differences for categorical 
and continuous variables. Meta-regression for con-
founders was done with restricted maximum likelihood 
with the Knapp Hartung modification for pruritic 
controls versus asymptomatic controls, multifetal 
pregnancy, and by study quality. We collected funnel 
plots and did the Harbord test to detect publication bias 
for each perinatal outcome reported, using log odds 
ratios for categorical variables. Variability between 
studies was determined by calculation of I² and τ² 
estimates of heterogeneity.
We did logistic regression for the IPD to obtain area 
under receiver operating characteristic (ROC) curves 
(ie, AUC) for the association between adverse perinatal 
outcomes and maximum serum total bile acids, alanine 
aminotransferase, aspartate aminotransferase, and bili-
rubin, for single and multifetal pregnancies, both 
individually and in combination.
Moreover, we did logistic regression using predefined 
total bile acid cutoffs of 20 µmol/L, 40 µmol/L, 60 µmol/L, 
80 µmol/L, 100 µmol/L, 120 µmol/L, 140 µmol/L and 
more than 150 µmol/L to determine thresholds above 
which stillbirth increased; we used step functions, 
defining dummy variables using 0 for all values below 
the threshold and 1 for all values equal to or above the 
threshold. We used stepwise regression to simplify the 
model and remove unneeded cutpoints using Stata’s 
stepwise regression command, which depends on the 
use of step functions, rather than non-overlapping 
categories.20,21 We calculated hazard ratios (HRs) using 
Cox proportional model from a survival analysis to 
determine the proportion of stillbirth and spontaneous 
preterm birth by gestational week between bile acid 
concentration categories, analysing fetuses at risk for 
each gestational week.22 Post-hoc analysis of stillbirth 
proportions by bile acid category compared with reported 
national stillbirth proportions was done with the bi-
nomial probability test.
We did the analyses with Stata version 13. This study is 
registered with PROSPERO, number CRD42017069134.23
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and final responsibility for the decision to 
submit for publication.
Results
23 studies reported intrahepatic cholestasis of pregnancy 
and control pregnant groups and fulfilled the inclusion 
criteria for the aggregate data meta-analysis comparing 
perinatal outcomes in intrahepatic cholestasis of preg-
nancy cases with controls (appendix). IPD was requested 
from these studies and 33 further studies (cases only 
without controls), including unpublished datasets from 
two hospital sites, with data received from 27 studies 
(ten case-control and 17 cases-only studies; figure 1; 
appendix).
Studies for which IPD were requested but were 
not received are listed in the appendix. Studies from 
Figure 1: Flow chart of search results
IPD=individual patient data.
2367 records identified through
database searches
2 additional records identified through other sources
1519 records screened
109 full-text articles assessed 
for eligibility
54 eligible studies
848 duplicates removed
1410 records excluded because topic was not relevant for the
research question
31 studies not eligible for aggregate data meta-analysis 
because control data was not included
55 full-text articles excluded
24 total bile acids not used in diagnosis, assessed, or available 
11 participants duplicated in another study
7 participant numbers too small
5 reasonable chance of bias in case selection
5 perinatal outcomes not recorded
2 ethical approval absent
1 manuscript was unavailable
23 studies included for 
aggregate data 
meta-analysis
170 680 participants included in 
aggregate data 
meta-analysis
5557 cases
165 123 controls
56 studies for which IPD were sought  
27 studies for which IPD 
were provided
10 from case-control 
studies
17 from cases-only 
studies
5269 participants for whom 
data were provided
29 studies for which IPD 
were not provided
18 no reply from 
authors
10 data not available
1 duplicate dataset
5473 participants for whom 
data were not provided
3411 included in 
aggregate data 
meta-analysis 
from 13 studies
2062 participants from 
16 studies not 
included in 
aggregate data 
meta-analysis
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Figure 2: Forest plots of 
selected perinatal outcomes 
from aggregated patient 
data
(A) Stillbirth; (B) spontaneous 
preterm birth; 
(C) meconium-stained 
amniotic fluid. Weights are 
from random effects analysis. 
ICP=intrahepatic cholestasis 
of pregnancy. OR=odds ratio. 
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Zhang et al26
Ataalla et al36
2·60 (1·62–4·16)
12·10 (4·31–34·01)
1·32 (0·88–1·99)
0·36 (0·08–1·68)
7·97 (4·71–13·47)
1·23 (0·50–3·01)
5·53 (1·15–26·55)
2·55 (1·20–5·42)
1·34 (0·76–2·37)
2·84 (1·92–4·19)
2·44 (1·36–4·37)
3·13 (0·98–9·98)
1·31 (0·94–1·84)
2·00 (0·51–7·79)
9·63 (2·01–46·13)
5·04 (1·11–22·76)
100·00
7·36
10·49
5·13
9·97
8·07
5·04
53·25
9·75
10·56
46·75
10·76
5·85
5·04
5·26
6·73
2/42
17/98
50/345
6/33
10/57
14/91
12/90
13/40
108/663
132/505
24/129
52/362
242/1205
350/1868
18/76
10/42
197/1725
2/50
4/40
2396/22 205
2/54
2011/16 818
10/90
2/42
217/2001
12/98
39/185
50/1793
62/1110
5/200
2179/20 204
5/55
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15 countries, from five continents, were included in the 
aggregate data meta-analysis, whereas IPD data were 
available from 14 countries, from five continents.
In the aggregate data meta-analysis, women with intra-
hepatic cholestasis of pregnancy had a slightly higher 
BMI than those with uncomplicated pregnancies (mean 
difference 1·6 kg/m² [SD 0·2]) and were more likely to 
be of Asian ethnicity (appendix). Additionally, a higher 
proportion of women with intrahepatic cholestasis of 
pregnancy had pre-eclampsia and gestational diabetes 
than those without intrahepatic cholestasis of pregnancy.
Women in the IPD analysis had similar bile acid 
concentrations to intrahepatic cholestasis of pregnancy 
cases extracted from the systematic review, and the 
proportion treated with ursodeoxycholic acid was similar 
(appendix). Median fasting bile acid concentrations 
(n=1726, 23·0 µmol/L [IQR 14·7–41]) and prandial bile 
acid concentrations (n=2795, 32·0 µmol/L [19·0–61·5]) 
were similar with analysis restricted to those values from 
unselected cohorts of women with intrahepatic cholestasis 
of pregnancy.
Meta-analyses of data from the systematic review showed 
that, compared with controls, women with intrahepatic 
cholestasis of pregnancy had a higher risk of spontaneous 
preterm birth (OR 3·47 [95% CI 3·06–3·95; figure 2] and 
iatrogenic preterm birth (OR 3·65 [1·94 to 6·85]; appendix). 
Compared with controls, babies of intrahepatic cholestasis 
of preg nancy pregnancies were more likely to have 
meconium-stained amniotic fluid (OR 2·60 [95% CI 
1·62–4·16]; figure 2) and be admitted to the neonatal 
unit (OR 2·12 [1·48–3·03]; appendix), but no difference 
was measured in birthweight centile (weighted mean 
difference 0·60 [95% CI –6·21 to 7·41]; appendix).
Findings from the meta-regression showed that study 
quality significantly contributed to the heterogeneity in 
results for meconium-stained amniotic fluid (p=0·0108); 
but multifetal pregnancies, controls comprising women 
with pruritus versus asymptomatic pregnancies, and 
study quality (according to Newcastle-Ottawa scale) did 
not significantly affect the results of other comparisons 
presented (appendix). The aggregate data meta-analysis 
showed the OR for stillbirth in women with intrahepatic 
cholestasis of pregnancy compared with controls to be 
1·46 (95% CI 0·73–2·89; figure 2); with significant 
between study heterogeneity (τ²=0·81, p=0·0016; 
I²=59·8%). Although other perinatal outcomes did not 
reveal publication bias, this bias was significant for the 
meta-analysis of neonatal unit admission (p=0·037). 
Outlying studies were identified from the funnel plot, 
and removed for a subsequent analysis, which resulted 
in intrahepatic cholestasis of pregnancy having an 
Figure 3: ROC curves for the association between stillbirth and serum biochemical markers for singleton 
pregnancies
(A) Association between stillbirth and peak TBA and ALT concentrations for singleton pregnancies in a subset of 
women (n=3601) who had both biochemical tests. (B) Association between stillbirth and peak TBA, ALT, AST, and 
bilirubin concentrations for singleton pregnancies in a subset of women (n=1738) who had all four biochemical 
tests. ALT=alanine aminotransferase. AST=aspartate aminotransferase. AUC=area under the curve. ROC=receiver 
operating characteristic. TBA=total bile acid. *TBA=100 µmol/L. †TBA=40 µmol/L. ‡ALT=40 IU/L. §AST=40 IU/L. 
¶Bilirubin=20 µmol/L.
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TBA: 0·94 (95% CI 0·91–0·97)
ALT: 0·56 (95% CI 0·26–0·85)
AST: 0·58 (95% CI 0·33–0·83)
Bili: 0·79 (95% CI 0·62–0·95)
ROC AUC
Bile acids Alanine aminotransferase Aspartate aminotransferase Bilirubin
n/N (%) ROC AUC (95% CI) n/N (%) ROC AUC (95% CI) n/N (%) ROC AUC (95% CI) n/N (%) ROC AUC (95% CI)
Stillbirth 25/4269 (1%) 0·83 (0·74–0·92) 22/3668 (1%) 0·46 (0·35–0·57) 17/3071 (1%) 0·49 (0·36–0·62) 13/2425 (1%) 0·57 (0·42–0·72)
Preterm birth 1256/4378 (29%) 0·60 (0·58–0·63) 583/1836 (32%) 0·55 (0·52–0·57) 583/1836 (32%) 0·54 (0·51–0·57) 583/1836 (32%) 0·57 (0·54–0·60)
Spontaneous preterm birth 383/4316 (9%) 0·61 (0·58–0·64) 141/1791 (8%) 0·59 (0·54–0·64) 141/1791 (8%) 0·59 (0·54–0·65) 141/1791 (8%) 0·57 (0·51–0·62)
Iatrogenic preterm birth 817/4316 (19%) 0·58 (0·55–0·60) 397/1791 (22%) 0·53 (0·50–0·56) 397/1791 (22%) 0·52 (0·50–0·55) 397/1791 (22%) 0·56 (0·53–0·59)
Meconium stained amniotic 
fluid
588/4032 (15%) 0·62 (0·59–0·64) 243/1605 (15%) 0·59 (0·55–0·63) 243/1605 (15%) 0·59 (0·56–0·63) 243/1605 (15%) 0·57 (0·53–0·61)
Non-reassuring heart rate 
monitoring
588/3057 (19%) 0·58 (0·55–0·60) 192/1379 (14%) 0·50 (0·46–0·55) 192/1379 (14%) 0·53 (0·49–0·58) 192/1379 (14%) 0·54 (0·49–0·58)
Apgar score <7 at 5 min 90/4181 (2%) 0·65 (0·58–0·71) 32/1698 (2%) 0·45 (0·36–0·54) 32/1698 (2%) 0·49 (0·40–0·58) 32/1698 (2%) 0·51 (0·40–0·62)
Umbilical cord arterial blood 
pH <7·0
1/2029 (1%) 0·68 (0·53–0·82) 6/630 (1%) 0·48 (0·21–0·76) 6/630 (1%) 0·49 (0·22–0·75) 6/630 (1%) 0·52 (0·23–0·81)
Neonatal unit admission 798/4014 (20%) 0·55 (0·52–0·57) 182/1533 (12%) 0·57 (0·53–0·62) 182/1533 (12%) 0·58 (0·54–0·63) 182/1533 (12%) 0·55 (0·51–0·60)
Neonatal death 7/2888 (<1%) 0·62 (0·38–0·86) 5/1391 (<1%) 0·56 (0·31–0·84) 5/1391 (<1%) 0·62 (0·38–0·87) 5/1391 (<1%) 0·68 (0·53–0·84)
ROC AUC=receiver operating characteristic area under curve.
Table: Summary of individual patient data associations between serum biochemistry and adverse perinatal outcome for singleton pregnancies
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attenuated effect on the increased risk of neonatal unit 
admission (OR 1·47 [1·03–2·10]; appendix).
IPD analysis showed that total bile acid concentrations 
were more highly predictive of stillbirth for singleton 
pregnancies than the other biomarkers assessed (ROC 
AUC 0·85 [95% CI 0·77–0·93]; figure 3A), whereas 
the associations between stillbirth and alanine amino-
transferase (ROC AUC 0·46 [95% CI 0·35–0·57]; 
figure 3A) and aspartate amino transferase (ROC AUC 
0·58 [0·33–0·83]; figure 3B) were lower than for total bile 
acid; bilirubin was also less predictive of stillbirth than 
was total bile acid (ROC AUC 0·79 [0·62 to 0·95]; 
figure 3B, table). These associations were not present in 
multifetal pregnancies, although the smaller numbers of 
multifetal pregnancies than singleton pregnancies 
reduced the reliability of these results (appendix). No 
other adverse perinatal outcomes were highly associated 
with any biochemical marker assessed (table). A sensi-
tivity analysis excluding unpublished studies made no 
diff erence to these conclusions (appendix). Treatment 
with ursodeoxy cholic acid did not significantly affect this 
association (appendix). To assess whether a threshold of 
total bile acid concentration associated with an increased 
risk of stillbirth could be defined, we did stepwise logistic 
regression between bile acid categories at 20 µmol/L 
intervals; for women with singleton pregnancies, total 
bile acids of 100 µmol/L or more were significantly 
associated with an increased risk of stillbirth (p<0·0001). 
The majority of women with intrahepatic cholestasis of 
pregnancy had maximum total bile acids of less than 
100 µmol/L (figure 4A; appendix); the increased risk of 
stillbirth thus was associated with a minority of women 
with intrahepatic cholestasis of pregnancy. The prevalence 
of stillbirth in singleton pregnancies was lowest for 
women with serum total bile acids of less than 40 µmol/L 
after 24 gestational weeks, and highest for those with 
total bile acids of 100 µmol/L or higher (figure 4A). 
A time-to-event analysis by each gestational week the 
fetus remained in utero for these bile acid categories 
(fetus at risk) for singleton pregnancies showed that the 
HR for stillbirth in women with bile acids of 40–99 µmol/L 
was not significant when compared with women with 
total bile acids of less than 40 µmol/L, whereas the HR 
for women with bile acids of 100 µmol/L or more was 
significant (figure 4B; appendix). The risk of stillbirth 
increased as gestation progressed (figure 4B). Similar 
results were obtained with a sensitivity analysis, assuming 
that all iatrogenic deliveries in the original survival 
analysis would not have been followed by a stillbirth 
before 40 gestational weeks (appendix).
To establish whether risk of stillbirth in women with 
total bile acids of less than 100 µmol/L was increased 
compared with the background population risk, we used 
published data on the prevalence of national stillbirth as 
comparator groups (appendix) in a weighted analysis.40 
We found no increased stillbirth risk for women with 
singleton intrahepatic cholestasis of pregnancy who were 
included in our IPD analysis with total bile acids of less 
than 40 µmol/L or 40–99 µmol/L when compared with the 
pooled national prevalence of stillbirth from 2000 (0·42%) 
or 2015 (0·33%).
Results from the aggregate data meta-analysis showed 
that women with intrahepatic cholestasis of pregnancy had 
higher ORs of preterm birth (OR 3·54 [95% CI 2·72–4·62]; 
Figure 4: Proportion of stillbirths, number of pregnancies, and time-to-event analysis, by total bile acid 
concentrations in singleton pregnancies with intrahepatic cholestasis of pregnancy
(A) Number of women with intrahepatic cholestasis of pregnancy (blue bars) and proportion of those women who 
had a stillbirth (red bars) by peak total bile acid category for women with singleton pregnancies. Stillbirth 
prevalence by total bile acid groups (<40 µmol/L, 40–99 µmol/L, and ≥100 µmol/L) is shown at the top of the graph. 
(B) Kaplan-Meir plot showing the proportion of fetuses in utero who were stillborn from 24 to 40 gestational weeks 
for singleton pregnancies. Data were analysed by completed gestational week categories, with alterations plotted 
mid-week to reflect uncertainty by individual day of change. Data are not shown from 40 weeks because of the low 
remaining numbers of fetuses in utero. HR=hazard ratio. ICP=intrahepatic cholestasis of pregnancy.
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appendix), but significant heterogeneity was observed 
between studies, particularly for iatrogenic preterm birth. 
Although the risk of preterm birth in women with 
intrahepatic cholestasis of pregnancy was significant, no 
strong association was measured between preterm birth 
and serum biochemistry (table). However, an increase in 
preterm birth was evident with more marked elevations of 
total bile acid concentrations (figure 5A). Increasing HRs 
for spontaneous preterm birth by gestational week were 
seen with increasing bile acid category (figure 5B; 
appendix).
The prevalence of iatrogenic preterm birth was high for 
all categories of bile acid concentration (<40 μmol/L, 
16·5% [95% CI 15·1–18·0]; 40–99 μmol/L, 19·1% 
[17·1–21·1]; and ≥100 μmol/L, 30·5% [26·8–34·6]). The 
majority of multifetal pregnancies were born preterm 
(appendix).
Discussion
This meta-analysis provides evidence that intrahepatic 
cholestasis of pregnancy is associated with adverse 
perinatal outcomes, with a significantly increased risk of 
stillbirth for women with serum total bile acids of 
100 µmol/L or more. Iatrogenic preterm birth is a major 
contributor to the higher prevalence of preterm birth in 
intrahepatic cholestasis of pregnancy (for women with 
any bile acid concentration) than in control pregnancies, 
although the prevalence of spontaneous preterm birth 
increases with higher total bile acid concentrations.
One of the strengths of this meta-analysis is the careful 
definition of cholestatic disease to include serum total 
bile acids in the diagnostic criteria, and supporting IPD 
providing the largest combined cohort to date of women 
with intrahepatic cholestasis of pregnancy to investigate 
the associations between biochemical abnormalities and 
adverse pregnancy outcomes. Given that stillbirth is a 
rare outcome, a cohort of this size is necessary to obtain 
reliable conclusions. A further strength is the collaborative 
use of data from multiple studies and centres. In 
particular, authors of smaller studies frequently state that 
larger studies are needed to substantiate findings with 
regard to stillbirth. Using previously collected data avoids 
research waste, as highlighted in the Lancet Series 
published in 2014.41 One limitation of the aggregate data 
meta-analysis is the inconsistency in the definition of 
perinatal out comes of neonatal asphyxia, resulting in 
difficulty with comparison of studies. The CoRe 
Outcomes in Women’s and Newborn health initiative42 
intends to address these difficulties, and with more 
widespread adoption, will enable meta-analyses to 
appraise such study outcomes.
A further challenge of this study was the inability to 
adjust results by all confounders because of incomplete 
reporting. Although we were able to do meta-regression 
for study-level confounders (multifetal pregnancy pro-
portions and study quality), individual patient char ac-
teristics, such as coexistent pre-eclampsia and ges tational 
diabetes, were not accounted for. Proportions of both 
diseases were higher in the populations of women with 
intrahepatic cholestasis of pregnancy compared with 
Figure 5: Proportion of preterm births, number of pregnancies, and time-to-event analysis, by total bile acid 
concentrations in singleton pregnancies with intrahepatic cholestasis of pregnancy
(A) Number of women with intrahepatic cholestasis of pregnancy (blue bars), and proportion of those women with 
overall preterm birth (red bars), spontaneous preterm birth by gestational week (green bars), and iatrogenic preterm 
birth by gestational week (purple bars), by peak total bile acid category for women with singleton pregnancies. 
Spontaneous preterm birth (more clinically relevant than overall preterm birth because it is not clinician dependent) 
prevalence by total bile acid groups (<40 µmol/L, 40–99 µmol/L, and ≥100 µmol/L or more) is shown at the top of the 
graph. (B) Kaplan-Meir plot showing the proportion of fetuses in utero who underwent spontaneous preterm birth 
from 24 to 37 gestational weeks for singleton pregnancies (birth from 37 gestational weeks is not considered 
preterm). Data were analysed by completed gestational week categories, with alterations plotted mid-week to reflect 
uncertainty by individual day of change. HR=hazard ratio. ICP=intrahepatic cholestasis of pregnancy.
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controls, as expected from previous literature.43,44 Previous 
studies have reported an association of maternal co-
morbidities (such as pre-eclampsia and gestational 
diabetes) with stillbirth in women with intrahepatic 
cholestasis of pregnancy and bile acids of more than 
40 µmol/L.7 Since increased bile acids are not a feature of 
either of these pregnancy complications, and the 
association between intrahepatic cholestasis of pregnancy 
and stillbirth has been reported with and without the 
comorbidities, this association is likely to be true, although 
the possibility of additive factors contributing to stillbirth 
risk remains likely.
Other small studies have previously suggested an 
association between intrahepatic cholestasis of pregnancy 
and adverse perinatal risks, but their clinical implications 
have been limited by their size.11,27,31,45 Cui and colleagues46 
did a meta-analysis with extracted data from women with 
intrahepatic cholestasis of pregnancy and showed that 
adverse perinatal outcomes (eg, preterm birth) were 
increased in women with bile acids greater than 40 µmol/L 
compared with women with lower bile acids, but did not 
report effects on stillbirth risks. Thus, the clear bile acid 
threshold of 100 µmol/L beneath which the prevalence of 
stillbirth was not increased is a novel and important 
finding in our study. This threshold was reached using 
bile acid concentrations obtained with differing methods 
(appendix), yet interlaboratory quality control procedures 
were likely to minimise the unreliability of measurements, 
and our findings reflect everyday clinical results.
Results from two studies have suggested the optimal 
delivery time for women with intrahepatic cholestasis of 
pregnancy to be 36 gestational weeks.47,48 Puljic and 
colleagues47 calculated a composite mortality risk by 
gestational week with data registries for 5545 Californian 
women with intrahepatic cholestasis of pregnancy and 
matched controls, identifying 36 weeks as the optimal 
delivery week to prevent stillbirth or neonatal death for 
singleton pregnancies. Their study reported an overall 
stillbirth prevalence of 0·64% for women with intra hep-
atic cholestasis of pregnancy and singleton pregnancies 
(similar to the 0·59% [95% CI 0·39–0·87] that we report 
in the IPD analysis), although the authors did not stratify 
women according to disease severity and did not account 
for additional neonatal morbidity secondary to prematurity. 
Lo and colleagues48 also identified 36 weeks to be the 
optimal gestation for delivery using computer modelling 
to determine subsequent maternal and child quality-
adjusted life-years achieved, compared with delivery at 
other gestations between 35 and 38 weeks. They estimated 
the prevalence of stillbirth in women with intrahepatic 
cholestasis of pregnancy to be 1·74%, and their model was 
robust to a stillbirth prevalence that was 30% higher (ie, up 
to 2·26%) and 60% lower (ie, down to 0·70%) than this 
estimate. However, when stratifying women according to 
their maximum bile acid con centration of greater or less 
than 100 µmol/L in our IPD analysis, stillbirth prevalence 
was outside of these ranges (0·13–0·28% for <100 µmol/L 
and 3·44% for ≥100 µmol/L), reducing the applicability of 
their model to our population.
Our study identifies a clear association between bile 
acid concentrations and stillbirth for singleton preg-
nancies. Importantly, the stillbirth risk was increased in 
women with total bile acid concentrations of 100 µmol/L 
or more at any point in the pregnancy. The HR for 
stillbirth increased with gestation time; the prevalence of 
stillbirth for all bile acid groups is less than 1% before 
35 completed weeks of pregnancy. For the women in our 
dataset with peak bile acid concentrations of less than 
100 µmol/L and singleton pregnancies, we found no 
increase in stillbirth compared with the background 
population risk before 39 weeks’ gestation; however, the 
25·3% preterm birth prevalence in this group, the largest 
proportion of which was iatrogenic, might have contrib-
uted to prevention of later stillbirth. The so-called fetus 
at risk approach used to determine HRs of stillbirth 
between women of different bile acid categories accounts 
for this background at risk approach, in part. This 
approach is more reliable when the denominator 
(number of fetuses in utero at the start of that gestational 
week) is large than when it is small (eg, in our study, at 
24 weeks, over 500 women were included with peak bile 
acids in the pregnancy of >100 µmol/L; however, at 
39 weeks, only 13 remained in the study). Since the 
majority of babies were born by 39 weeks’ gestation, we 
did not present stillbirth beyond that gestation because 
the number at risk would be too low for the results to be 
clinically meaningful and the uncertainty rendered the 
findings clinically unreliable. However, we recognise the 
limitations of our approach; such biases are inevitable in 
a non-randomised study and bias correction is not always 
possible. Although the most reliable solution is to do a 
randomised controlled trial addressing the question, a 
pilot timing-of-delivery trial in women with intrahepatic 
cholestasis of pregnancy concluded that a randomised 
trial was unlikely to be feasible49 and the challenges of 
designing such a trial have been widely recognised 
because of the rarity of stillbirth as a pregnancy out-
come.50 A systematic review by Henderson and col-
leagues14 concluded that evidence was insufficient to 
support the practice of active management (ie, proactively 
arranging delivery) for intrahepatic cholestasis of 
pregnancy. The increased risk of stillbirth in women with 
bile acids of >100 µmol/L or more suggests that active 
management (most likely to be undertaken in women 
with the highest concentrations of bile acids) does not 
completely eliminate the risk of stillbirth. Although our 
data cannot confirm that the risk of stillbirth is not 
increased for women with bile acids of less than 
100 µmol/L compared with the background population if 
not actively managed, these women were unlikely to be 
managed more proactively than those with bile acids 
of 100 µmol/L or more. Women included in our IPD 
cohort were unlikely to have not received antenatal care, 
which in itself is associated with an increased risk for 
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antepartum stillbirth,51 and this confounder might have 
contributed to the low prevalence of stillbirth observed 
for women with bile acids of less than 100 µmol/L in 
comparison with national stillbirth proportions.
Peak total bile acid concentrations were associated with 
stillbirth risk, whether or not women were taking urso-
deoxycholic acid. This analysis was not designed to 
determine whether ursodeoxycholic acid treatment 
can reduce the risk of stillbirth, which would be best 
addressed by randomised controlled trials such as the 
PITCHES randomised controlled trial, which is in 
progress in the UK.52
Two suggested models of fetal demise in intrahepatic 
cholestasis of pregnancy are consistent with evidence 
indicating that high bile acids contribute to the causes of 
adverse outcomes: increased bile acids are associated 
with fetal cardiac arrhythmia and placental vessel 
spasm.53,54 Without data on the timings of peak bile acid 
concentration and associated stillbirth gestation, this 
study cannot provide further mechanistic evidence to 
support these models; as such, we suggest managing 
women with intrahepatic cholestasis of pregnancy and 
singleton pregnancies on the basis of their peak bile acid 
concentration. Because bile acids can change rapidly 
with advancing gestation,55 regular monitoring of serum 
total bile acids (eg, weekly) is needed to reassess risk. Bile 
acids might increase postprandially; the conclusions of 
the IPD meta-analysis were based on a mixed population 
of sampling protocols, with the majority of studies using 
non-fasting measurements, but the median bile acid 
concentrations were similar whether measured when 
fasting or postprandially.
In summary, this study has clarified the adverse 
pregnancy outcomes associated with intrahepatic 
choles tasis of pregnancy and has identified that women 
with serum bile acids of 100 µmol/L or more have a 
significantly increased risk of stillbirth. Future research 
should target mechanistic explanations for the increased 
risk of stillbirth in intrahepatic cholestasis of pregnancy 
and the potential of specific treatments to prevent fetal 
death.
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